aplastic anemia | Page 43 | Aplastic Anemia & MDS International Foundation

aplastic anemia

Eltrombopag and improved hematopoiesis in refractory aplastic anemia

Author(s): 
Olnes MJ, Scheinberg P, Calvo KR, Desmond R, Tang Y, Dumitriu B, Parikh AR, Soto S, Biancotto A, Feng X, Lozier J, Wu CO, Young NS, Dunbar CE
Primary Author: 
Olnes MJ
Journal Title: 
N Engl J Med
Original Publication Date: 
Jul 2012

BACKGROUND:

Severe aplastic anemia, which is characterized by immune-mediated bone marrow hypoplasia and pancytopenia, can be treated effectively with immunosuppressive therapy or allogeneic transplantation. One third of patients have disease that is refractory to immunosuppression, with persistent, severe cytopenia and a profound deficit in hematopoietic stem cells and progenitor cells. Thrombopoietin may increase the number of hematopoietic stem cells and progenitor cells.

METHODS:

Bone Marrow Diseases: 

Different outcomes between cyclophosphamide plus horse or rabbit antithymocyte globulin for HLA-identical sibling bone marrow transplantation in severe aplastic anemia

Author(s): 
Atta EH, de Sousa AM, Schirmer MR, Bouzas LF, Nucci M, Abdelhay E
Primary Author: 
Atta EH
Journal Title: 
Biol Blood Marrow Transplant
Original Publication Date: 
Jul 2012

The standard regimen for HLA-identical sibling

Bone Marrow Diseases: 

Immune markers of disease severity and treatment response in pediatric acquired aplastic anemia

Author(s): 
Sutton KS, Shereck EB, Nemecek ER, Kurre P
Primary Author: 
Sutton KS
Journal Title: 
Pediatr Blood Cancer
Original Publication Date: 
Jul 2012

BACKGROUND:

To investigate the immune status among pediatric patients with aplastic anemia (AA) and explore PNH-status, T-regulatory and NK-cell frequency as potential markers of clinical response.

METHODS:
Data were retrospectively analyzed from twenty-six patients diagnosed with AA. PNH populations, T- and NK-subsets were determined via flow cytometry.

RESULTS:

Bone Marrow Diseases: 

Michael Keng, MD

Keng, Michael
Assistant Professor, Division of Hematology/Oncology
University of Virginia Cancer Center

Dr. Michael Keng holds a clinical faculty appointment in Medicine in the Division of Hematology/Oncology at UVA Cancer Center. He practices at the Emily Couric Clinical Cancer Center in Charlottesville and serves as an inpatient hematologist at UVA Hospital.

Alternative donor HSCT in refractory acquired aplastic anemia - Prevention of graft rejection and graft versus host disease by immunoablative conditioning and graft manipulation

Author(s): 
Urban C, Benesch M, Sovinz P, Sipurzynski S, Lackner H, Müller E, Schwinger W
Primary Author: 
Urban C
Journal Title: 
Pediatr Transplant
Original Publication Date: 
Mar 2012

Urban C, Benesch M, Sovinz P, Sipurzynski S, Lackner H, Müller E, Schwinger W. Alternative donor HSCT in

Bone Marrow Diseases: 

Prospective study of rabbit antithymocyte globulin and cyclosporine for aplastic anemia from the EBMT Severe Aplastic Anaemia Working Party

Author(s): 
Marsh JC, Bacigalupo A, Schrezenmeier H, Tichelli A, Risitano AM, Passweg JR, Killick SB, Warren AJ, Foukaneli T, Aljurf M, Al-Zahrani HA, Schafhausen P, Roth A, Franzke A, Brummendorf TH, Dufour C, Oneto R, Sedgwick P, Barrois A, Kordasti S, Elebute MO,
Primary Author: 
Marsh JC
Journal Title: 
Blood
Original Publication Date: 
Apr 2012

Rabbit

Bone Marrow Diseases: